Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants

Scott, Jeffrey F.; Brough, Kevin; Grigoryan, Konstantin V.; Muzic, John G.; Kim, Grace Y.; Conic, Rosalynn R.Z.; Hill, Sheena T.; Brewer, Jerry D.; Baum, Christian L.; Litzow, Mark R.; Patnaik, Mrinal M.; Hashmi, Shahrukh K.; Lazarus, Hillard M.; Bordeaux, Jeremy S.; Thompson, Cheryl L.; Gerstenblith, Meg R.; Lehman, Julia S.

doi:10.1001/jamadermatol.2020.0559

Cited by 12 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We further investigated the predictive value of ME, PS-I, and PS-II on the development of keratinocyte carcinoma because recent reports suggest that risk factors associated with keratinocyte carcinoma could differ from those of other SSCs. 28,30 The patient-and transplantation-related risk factors for keratinocyte carcinoma were similar to those for any SSC in univariable analysis (Table S2). High disease risk index, and GVHD prophylaxis regimen (Table 5).…”

Section: Association Of Me Ps-i and Ps-ii In The Gvh Direction And De...mentioning

confidence: 69%

“…Keratinocyte carcinomas, including basal cell carcinoma and squamous cell carcinoma, comprised 69.5% of all SSCs in our cohort. We further investigated the predictive value of ME, PS‐I, and PS‐II on the development of keratinocyte carcinoma because recent reports suggest that risk factors associated with keratinocyte carcinoma could differ from those of other SSCs 28,30 . The patient‐ and transplantation‐related risk factors for keratinocyte carcinoma were similar to those for any SSC in univariable analysis (Table S2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Molecular disparity of HLA‐DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation

Zou

Kongtim

Oran

et al. 2023

Cancer

View full text Add to dashboard Cite

Background: An increased incidence of subsequent solid cancers (SSCs) has been reported in long-term survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and SSC is associated with inferior mortality and morbidity.Previous studies showed that the incidence of SSC is significantly higher in those who underwent allo-HSCT from HLA-mismatched donors, suggesting that persistent alloimmunity may predispose patients to SSCs. It was recently reported that, in a cohort of patients who received allo-HSCT from an unrelated donor matched at HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 loci, HLA-DPB1 alloimmunity determined by high mismatched eplets (MEs) and Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) score (PS), was associated with relapse protection and increased risk of acute graft-versus-host disease (GVHD). Methods:In the present study, the impact of HLA-DPB1 alloimmunity assessed by molecular mismatch algorithms on the development of SSCs in a cohort of 1514 patients who underwent allo-HSCT for hematologic malignancies was further investigated. ME load at the HLA-DPB1 locus was measured using the HLA-Matchmaker module incorporated in HLA Fusion software, and the PS for mismatched HLA-DPB1 was calculated using the HSCT module from the PIRCHE online matching service. Results:In multivariable analysis after adjusting for baseline risk factors, higher ME, PS-I, and PS-II in the GVH direction, but not in the HVG direction, were associated with an increased risk of SSCs (ME: subdistribution hazard ratio [SHR] 1.58, p = .01; PS-I: SHR 1.59, p = .009; PS-II: SHR 1.71, p = .003). In contrast, nonpermissive HLA-DPB1 mismatches defined by the conventional T-cell epitope algorithm were not predictive of the risk of SSCs. Moreover, posttransplant cyclophosphamide-based GVHD prophylaxis was associated with a reduced risk of SSC (SHR 0.34, p = .021).

show abstract

Section: Association Of Me Ps-i and Ps-ii In The Gvh Direction And De...mentioning

confidence: 69%

Section: Resultsmentioning

confidence: 99%

Molecular disparity of HLA‐DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation

Zou

Kongtim

Oran

et al. 2023

Cancer

View full text Add to dashboard Cite

show abstract

“…Hematopoietic cell transplantation recipients have shown a modest risk of skin cancer ( 31 ). Age, chronic lymphocytic leukemia, clinically photodamaged skin, and history of cSCC have been defined as independent risk factors for developing cSCC in these patients ( 32 ). Interestingly, an azathioprine-specific genetic signature 32 could be detected in both well and poorly differentiated cSCC.…”

Section: Resultsmentioning

confidence: 99%

Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma

Helbig

2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundAtypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are increasingly common sarcomas of the skin with a genetic UV signature. Immunosuppression is a known risk factor for developing other UV-induced skin cancers such as cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), and Merkel cell carcinoma with increased mortality. In case reports or small case series of AFX/PDS patients, immunosuppression has been hypothesized as a risk factor for the development of distant metastases. The aim of the present study was to analyze immunosuppression as a risk factor for AFX/PDS in a large patient cohort.MethodsA cohort of 164 patients with AFX/PDS (47 AFX and 117 PDS) was collected between 2003 and 2021 and analyzed for clinicopathological data with a special focus on immunosuppression.ResultsOf all patients, 29.9% had any kind of immunosuppression; 6.4% of the AFX and 12.0% of the PDS patients had underlying hemato-oncological diseases. Patients with immunosuppression due to an underlying hemato-oncological disease had a significantly increased risk of progressing to (p = 0.010) and developing distant organ metastases (p = 0.000).ConclusionsImmunosuppression seems to be a risk factor for developing AFX/PDS with worse clinical outcomes. Therefore, immunosuppression, especially underlying hemato-oncological diseases, should be considered in the treatment and follow-up care of patients with AFX/PDS.

show abstract

“…Finally, they reviewed the full text in the remaining studies to confirm compliance with the eligibility criteria for inclusion and exclusion and established an Excel spreadsheet for data extraction, which was independently completed by four researchers. The extracted data were as follows: (1) publication details (title; author; and year); (2) For some studies lacking data, we attempted to contact the study authors to obtain more information. However, we have only received a response from one study author stating that the study author was unable to provide raw data as this was a preliminary study.…”

Section: Data Extractionmentioning

confidence: 99%

“…It most often presents as symmetric irregular light-to-dark brown macules and patches that occur primarily on sun-exposed areas of the face. It is more prevalent in Fitzpatrick skin types III–V [Fitzpatrick skin type is a numerical classification used for measuring human skin pigmentation and sun sensitivity ( 2 )], thus more often seen in Asians and Latin Americans ( 3 ). Although the precise cause of melasma remains elusive, however, multiple factors can trigger or aggravate it: ultraviolet radiation exposure, endocrine factors, genetic factors, medications containing phototoxic agents, ingredients of certain cosmetics, and psychological stress ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Prevalence of depression in melasma: a systematic review and meta-analysis

Chen,

Wan,

Sun

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundDue to cosmetic disfigurement, melasma can negatively affect the quality of life and emotional and mental health, further leading to depression.ObjectivePrevalence rates of depression in patients with melasma vary widely across studies. The aim of this systematic review and meta-analysis was to estimate the prevalence of depression among melasma patients.MethodsThe PubMed, Embase, Web of Science, and Scopus databases were searched to identify articles evaluating the prevalence of depression in melasma patients from their inception to 12 July 2023. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and a meta-analysis was performed using the Stata 14.0 software.ResultsSixteen studies met the eligibility criteria out of the 859 studies, containing a total of 2,963 melasma patients for this systematic review and meta-analysis. Meta-analyses revealed that the pooled prevalence of depression among patients with melasma was 43.4% (95% CI 30.5–56.2%, Q-value = 808.859, d.f. = 15, p < 0.001, tau2 = 0.065, I2 = 98.1%). The meta-regression found that the publication year, sample size, and study quality were not significant moderators for the observed heterogeneity in prevalence. A subgroup analysis according to depression assessment methods showed that the prevalence of depressive disorders was 24.2% (95% CI 16.8–31.6%), and the prevalence of depressive symptoms was 45.1% (95% CI 31.2–59.0%). A subgroup analysis by geographic regions showed that patients in Asia had the highest prevalence of depression at 48.5% (95% CI 26.0–71.0%), compared to other regions. A subgroup analysis by study design showed that the prevalence of depression in case–control studies was almost identical to cross-sectional studies. In the case of OR, the pooled OR of depression between patients with melasma and health controls was 1.677 (95% CI 1.163–2.420, p = 0.606, I2 = 0.0%).ConclusionThe prevalence of depression was relatively high in patients with melasma, and there was a correlation between melasma and depression, encouraging clinicians to screen for depression in their patients and providing a combination of physical and psychosocial support. If necessary, they should be referred to formal mental health services to seek professional psychological intervention.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, CRD42022381378.

show abstract

Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants

Cited by 12 publications

References 47 publications

Molecular disparity of HLA‐DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation

Molecular disparity of HLA‐DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation

Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma

Prevalence of depression in melasma: a systematic review and meta-analysis

Contact Info

Product

Resources

About